天康生物跌2.07%，成交额1.23亿元，主力资金净流出1964.05万元

Core Viewpoint - TianKang Biological experienced a stock price decline of 2.07% on December 1, with a current price of 7.11 CNY per share and a total market capitalization of 9.707 billion CNY [1] Company Overview - TianKang Biological Co., Ltd. is located in Urumqi, Xinjiang, and was established on December 28, 2000, with its stock listed on December 26, 2006 [1] - The company's main business includes the production and sales of biological vaccines for livestock and poultry, feed, and plant protein, as well as breeding, pig farming, slaughter processing, and meat product sales [1] - The revenue composition of the main business includes: 32.20% from pig farming, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1] Financial Performance - For the period from January to September 2025, TianKang Biological achieved an operating income of 13.610 billion CNY, representing a year-on-year growth of 4.00%, while the net profit attributable to the parent company was 412 million CNY, a decrease of 27.20% year-on-year [2] - The company has distributed a total of 1.891 billion CNY in dividends since its A-share listing, with 598 million CNY distributed in the past three years [3] Shareholder Information - As of November 20, 2025, the number of shareholders of TianKang Biological was 63,100, an increase of 7.39% from the previous period, with an average of 21,631 circulating shares per person, a decrease of 6.88% [2] - Notable institutional holdings include Guotai Zhongzheng Livestock Breeding ETF as the fifth largest shareholder with 24.296 million shares, and Hong Kong Central Clearing Limited as the seventh largest shareholder with 15.029 million shares, marking a new entry [3]